Drug utilization study and safety evaluation based on prediction approach for drug interactions in chemotherapy

本研究的目的是描述抗癌药物和包括坎波药在内的辅助药物在化疗中的应用，并对联合药物在化疗中的安全性进行评价。结果，在分别接受紫杉醇或伊立替康治疗的患者中，联合使用Daikichuto或Hangeshashinto，根据不良事件通用术语标准v4，显示出与3级以上的血小板计数下降显著相关。0个条件。此外，一些联合使用的Kampo药物可能会影响不良反应的发生，如骨髓抑制、电解质异常或肝功能障碍。

The aim of this study was to describe utilization of anticancer drugs and concomitant medicines including Kanpo medicines, and evaluate safety of concomitant Kampo medicines in chemotherapy. As a result, Co-administration of Daikenchuto or Hangeshashinto, in patients treated with paclitaxel or irinotecan, respectively, showed significant association with decrease of platelet count over grade 3 based on Common Terminology Criteria for Adverse Events v4. 0 criteria. In addition, some of co-administrated Kampo medicines could affect occurrence of adverse effects, such as myelosuppression, electrolyte abnormality, or hepatic dysfunction.